| Literature DB >> 31614893 |
Zhi-Gao Wang1, Xiao-Guo Ying2, Peng Gao3, Chun-Li Wang4, Yi-Fan Wang5, Xin-Wei Yu6, Jing Chen7, Bin Wang8, Hong-Yu Luo9.
Abstract
In this paper, the effect of skipjack (Katsuwonus pelamis) enzymatic peptide (SEP), which was prepared and purified from a byproduct of skipjack, on inflammation, ulcerative colitis and the regulation of intestinal flora was studied in a mouse ulcerative colitis model and a transgenic zebrafish inflammation model. The aggregation of transgenic granulocyte neutrophils in zebrafish from a normal environment and from a sterile environment was calculated, and the anti-inflammatory activity of SEP was evaluated. To evaluate the anti-ulcerative colitis activity of SEP, DSS-induced colitis mice were given SEP, salicylazosulfapyridine (SASP), or SASP + SEP. Then, the concentrations of IL-6, IL-10 and TNF-α in the serum were detected, the HE-stained colon tissue was examined by microscopy the species composition and abundance distribution of the intestinal flora was analyzed. The results showed that 500 μg/mL SEP treatment significantly alleviated neutrophil granulocyte aggregation in the zebrafish inflammation model; Diarrhea, hematochezia and body weight loss were alleviated to a certain extent in mice gavaged with SEP and SASP, and the combination of SASP with SEP was the most effective in mice. The damage to villi in the intestine was completely repaired, and the levels of IL-6, IL-10 and TNF-α, which are associated with inflammation, were all reduced. In addition, the proportion of intestinal probiotics or harmless bacteria increased, while that of pathogenic bacteria decreased, and the effect of the combined treatment was the most pronounced. These results show that SEP could relieve inflammation, cure ulcerative colitis, regulate intestinal flora and enhance the therapeutic effect of the clinical drug SASP. This study provides a theoretical basis for the development of SEP as an anti-inflammatory adjuvant therapy and intestinal flora regulator.Entities:
Keywords: intestinal flora; neutrophil granulocytes; skipjack enzymatic peptide; transgenic zebrafish; ulcerative colitis
Mesh:
Substances:
Year: 2019 PMID: 31614893 PMCID: PMC6835902 DOI: 10.3390/md17100582
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Summary of zebrafish toxicity symptoms in each group (n = 30).
| Groups | Experimental Concentration (μg/mL) | Death Number | Death Rate (%) | Toxicity Performance |
|---|---|---|---|---|
| Normal | - | 0 | 0 | - |
| Model | - | 0 | 0 | - |
| Solvent control (1% DMSO) | - | 0 | 0 | - |
| SEP | 31.25 | 0 | 0 | - |
| 62.5 | 0 | 0 | - | |
| 125 | 0 | 0 | - | |
| 250 | 0 | 0 | - | |
| 500 | 0 | 0 | - | |
| 1000 | - | - | precipitated | |
| 1500 | - | - | precipitated | |
| 2000 | - | - | precipitated |
Figure 1Number of neutrophils in zebrafish in each group. Compared with the model group: ### p < 0.001. Compared with the solvent control group: *** p < 0.001.
Figure 2Inflammation abatement effect in each group of zebrafish. Compared with the solvent control group: *** p < 0.001.
Figure 3Phenotype diagram of the effect of different treatments on inflammation in zebrafish. Note: the yellow arrows indicate neutrophil in the inflammation site.
Figure 4Daily weight change and disease activity index (DAI) score change of mice.
Figure 5Morphological changes in the colon tissue from mice in each group (HE staining). A. normal; B. model; C. Low-dose SEP; D. High-dose SEP; E. SASP; and F. SASP + SEP.
Figure 6Levels of IL-10, IL-6 and TNF-α in the serum of mice in each group. Note: a–f Values with same letters indicate no significant difference (p > 0.05).
Sequence statistics.
| Group | Effective Sequence Number | Total Number of Bases (bp) | Average Length (bp) | OTUs |
|---|---|---|---|---|
| Low-dose SEP | 60,532 | 25,733,194 | 425 | 42 |
| High-dose SEP | 55,524 | 23,536,705 | 423 | 99 |
| DSS | 57,059 | 24,402,954 | 427 | 37 |
| SASP | 61,383 | 26,198,618 | 426 | 96 |
| SASP + SEP | 56,461 | 23,894,720 | 423 | 223 |
| Normal | 56,461 | 18,667,293 | 416 | 244 |
Figure 7Chao1 dilution curve.
Figure 8Observed species dilution curve.
Figure 9Phylum-level barplot of mouse intestinal flora.
Main colony composition of mice at the phylum level.
| Low-dose SEP | High-dose SEP | DSS | SASP | SASP + SEP | Normal | |
|---|---|---|---|---|---|---|
| Proteobacteria | 74.65 (%) | 70.52 (%) | 79.12 (%) | 64.89 (%) | 61.23 (%) | 7.74 (%) |
| Bacteroidetes | 18.31 (%) | 10.12 (%) | 0.3357 (%) | 13.96 (%) | 23.87 (%) | 63.88 (%) |
| Firmicutes | 6.28 (%) | 15.86 (%) | 20.54 (%) | 12.14 (%) | 11.78 (%) | 14.18 (%) |
Figure 10Composition of mouse intestinal flora at the family level.
Mouse grouping and dosing regimen.
| Groups | Number of Mice | Induction Drug | Gavage Drugs |
|---|---|---|---|
| Normal | 10 | Water | Saline |
| Model | 10 | 3% DSS | Saline |
| Low-dose SEP | 10 | 3% DSS | 1 g SEP /100 mL |
| High-dose SEP | 10 | 3% DSS | 3 g SEP /100 mL |
| SASP | 10 | 3% DSS | 2 g SASP /100 mL |
| SASP + SEP | 10 | 3% DSS | (2 g SASP + 3 g SEP)/100 mL |
Note: SASP was used as a positive control drug for the clinical treatment of UC.
Figure 11DSS-induced UC mouse model method.